Dataset Information

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

ABSTRACT: RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients who have undergone autologous stem cell transplant for high-risk lymphoma or multiple myeloma.

DISEASE(S): Multiple Myeloma And Plasma Cell Neoplasm,Small Intestine Cancer,Angioimmunoblastic T-cell Lymphoma,Plasmacytoma,Lymphoma,Intestinal Neoplasms,Neoplasms, Plasma Cell,Multiple Myeloma

PROVIDER: 2047201 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:In regenerative medicine, histocompatibility of pluripotent stem cells is required to solve the problem of immunorejection after therapeutic transplantation. In this study, we show that autologous germline stem cells (GSCs), often called spermatogonial stem cells, could be derived by testis biopsy from individual mice and that GSCs subsequently could be dedifferentiated into autologous germline-derived pluripotent stem (gPS) cells. The establishment of GSCs by testicular biopsy in the mouse model can prove the principle of human clinical application to derive autologous GSCs to generate patient-specific pluripotent cells for regenerative medicine. For transcriptome profiling, 400 ng of total DNA-free RNA was used as input for labelled cRNA synthesis (Illumina TotalPrep RNA Amplification Kit - Ambion) following the manufacturer's instructions (IVT: 12h). Quality-checked cRNA samples were hybridized as biological or technical duplicates for 18 h onto mouse-8 v2 expression BeadChips (Illumina), washed, stained, and scanned following guidelines and using materials / instrumentation supplied / suggested by the manufacturer 13 samples were analyzed, GSC1: Mouse Germ Stem Cells OG2, line 1 (1 replicate); GSC2: Mouse Germ Stem Cells OG2, line 2 (1 replicate); GSC3: Mouse Germ Stem Cells OG2, line 3 (1 replicate); GSCr1: Mouse Germ Stem Cells OG2-ROSA, line 1 (1 replicate); GSCr2: Mouse Germ Stem Cells OG2-ROSA, line 2 (2 replicate); GSCr3: Mouse Germ Stem Cells OG2-ROSA, line 3 (1 replicate); ESC: Mouse Embryonic Stem Cells (duplicate) gPS1: Mouse clonal germ Pluripotent Stem cells from OG2, line 1, (1 replicate); gPS2: Mouse clonal germ Pluripotent Stem cells from OG2, line 2, (1 replicate); gPS3: Mouse clonal germ Pluripotent Stem cells from OG2, line 3, (1 replicate); gPSr1: Mouse clonal germ Pluripotent Stem cells from OG2-ROSA, line 1, (1 replicate); gPSr2: Mouse clonal germ Pluripotent Stem cells from OG2-ROSA, line 2, (1 replicate); gPSr3: Mouse clonal germ Pluripotent Stem cells from OG2-ROSA, line 3, (1 replicate).

Dataset Information

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure